Comprehensive molecular mechanisms and clinical therapy in nonalcoholic steatohepatitis: An overview and current perspectives
出版年份 2022 全文链接
标题
Comprehensive molecular mechanisms and clinical therapy in nonalcoholic steatohepatitis: An overview and current perspectives
作者
关键词
-
出版物
METABOLISM-CLINICAL AND EXPERIMENTAL
Volume 134, Issue -, Pages 155264
出版商
Elsevier BV
发表日期
2022-07-08
DOI
10.1016/j.metabol.2022.155264
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Fenofibrate Mitigates Hypertriglyceridemia in Nonalcoholic Steatohepatitis Patients Treated With Cilofexor/Firsocostat
- (2022) Eric J. Lawitz et al. Clinical Gastroenterology and Hepatology
- Niemann-Pick C1-Like 1 inhibitors for reducing cholesterol absorption
- (2022) Renshuai Zhang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Role of Microbiota-Derived Metabolites in Alcoholic and Non-Alcoholic Fatty Liver Diseases
- (2022) Ji-Won Park et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- SGLT2 Inhibitors as the Most Promising Influencers on the Outcome of Non-Alcoholic Fatty Liver Disease
- (2022) Luigi Mirarchi et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial
- (2022) Naim Alkhouri et al. JOURNAL OF HEPATOLOGY
- Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): a randomised, double-blind, placebo-controlled, phase 2b trial
- (2022) Stephen A Harrison et al. Lancet Gastroenterology & Hepatology
- NAFLD as a metabolic disease in humans: A literature review
- (2021) Bertrand Cariou et al. DIABETES OBESITY & METABOLISM
- Nonalcoholic fatty liver disease: another leap forward
- (2021) Manal F. Abdelmalek Nature Reviews Gastroenterology & Hepatology
- Fibroblast Growth Factor 19: Potential modulation of hepatic metabolism for the treatment of non‐alcoholic fatty liver disease
- (2021) Christina M. Sciarrillo et al. LIVER INTERNATIONAL
- Pharmacologic inhibition of Ketohexokinase prevents fructose-induced metabolic dysfunction
- (2021) Jemy A. Gutierrez et al. Molecular Metabolism
- Non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH)-related liver fibrosis: mechanisms, treatment and prevention
- (2021) Frank Tacke et al. Annals of Translational Medicine
- Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator‐activated receptor α modulator (SPPARMα), versus placebo in patients with non‐alcoholic fatty liver disease
- (2021) Atsushi Nakajima et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Posttranslational Regulation of HMG CoA Reductase, the Rate-Limiting Enzyme in Synthesis of Cholesterol
- (2021) Marc M. Schumacher et al. Annual Review of Biochemistry
- Hepatic Fat Reduction Due to Resmetirom in Patients With Nonalcoholic Steatohepatitis Is Associated With Improvement of Quality of Life
- (2021) Zobair M. Younossi et al. Clinical Gastroenterology and Hepatology
- TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial
- (2021) Rohit Loomba et al. GASTROENTEROLOGY
- Efficacy and safety of apararenone (MT‐3995) in patients with nonalcoholic steatohepatitis: A randomized controlled study
- (2021) Takeshi Okanoue et al. HEPATOLOGY RESEARCH
- A new mechanism of obeticholic acid on NASH treatment by inhibiting NLRP3 inflammasome activation in macrophage
- (2021) Suling Huang et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial
- (2021) Stephen A. Harrison et al. NATURE MEDICINE
- Apoptotic cell signals and heterogeneity in macrophage function: Fine-tuning for a healthy liver
- (2021) Imke Liebold et al. SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY
- Safety, Pharmacokinetics, Pharmacodynamics, and Formulation of Liver‐Distributed Farnesoid X‐Receptor Agonist TERN‐101 in Healthy Volunteers
- (2021) Yujin Wang et al. Clinical Pharmacology in Drug Development
- Structural insights into the mechanism of human NPC1L1-mediated cholesterol uptake
- (2021) Miaoqing Hu et al. Science Advances
- A new perspective on NAFLD: Focusing on lipid droplets
- (2021) Eleonora Scorletti et al. JOURNAL OF HEPATOLOGY
- Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial
- (2021) V. Ratziu et al. NATURE MEDICINE
- ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials
- (2021) Roberto A. Calle et al. NATURE MEDICINE
- A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH
- (2021) Sven M. Francque et al. NEW ENGLAND JOURNAL OF MEDICINE
- EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study
- (2021) Vlad Ratziu et al. JOURNAL OF HEPATOLOGY
- Pegbelfermin (BMS-986036): an investigational PEGylated fibroblast growth factor 21 analogue for the treatment of nonalcoholic steatohepatitis
- (2020) Cristy R.C. Verzijl et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Cenicriviroc Treatment for Adults with Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study
- (2020) Vlad Ratziu et al. HEPATOLOGY
- Cilofexor, a Nonsteroidal FXR Agonist, in Non‐Cirrhotic Patients with Nonalcoholic Steatohepatitis: A Phase 2 Randomized Controlled Trial
- (2020) Keyur Patel et al. HEPATOLOGY
- Selonsertib for Patients with Bridging Fibrosis or Compensated Cirrhosis Due to NASH: Results from Randomized Ph III STELLAR Trials
- (2020) Stephen A. Harrison et al. JOURNAL OF HEPATOLOGY
- The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease
- (2020) F. Anthony Romero et al. JOURNAL OF MEDICINAL CHEMISTRY
- Hepatocyte apoptosis is tumor promoting in murine nonalcoholic steatohepatitis
- (2020) Petra Hirsova et al. Cell Death & Disease
- c-Mpl and TPO expression in the human central nervous system neurons inhibits neuronal apoptosis
- (2020) Liang Li et al. Aging-US
- Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges
- (2020) Jean-François Dufour et al. GUT
- The L‐α‐lysophosphatidylinositol/GPR55 system induces the development of non‐alcoholic steatosis and steatohepatitis
- (2020) Marcos F. Fondevila et al. HEPATOLOGY
- Antidiabetic Therapy in the Treatment of Nonalcoholic Steatohepatitis
- (2020) Yoshio Sumida et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Volixibat in adults with non-alcoholic steatohepatitis: 24-week interim analysis from a randomized, phase II study
- (2020) Philip N. Newsome et al. JOURNAL OF HEPATOLOGY
- Evaluation of NAFLD and fibrosis in obese patients – a comparison of histological and clinical scoring systems
- (2020) Sophia Marie-Therese Schmitz et al. BMC GASTROENTEROLOGY
- Evolving role for pharmacotherapy in NAFLD/NASH
- (2020) Suzanna L. Attia et al. CTS-Clinical and Translational Science
- Bile acid modulators for the treatment of nonalcoholic steatohepatitis (NASH)
- (2020) Stefano Fiorucci et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Acetyl-CoA Carboxylase Inhibition Improves Multiple Dimensions of NASH Pathogenesis in Model Systems
- (2020) Trenton T. Ross et al. Cellular and Molecular Gastroenterology and Hepatology
- Semaglutide for the treatment of non-alcoholic steatohepatitis: Trial design and comparison of non-invasive biomarkers
- (2020) Stephen A. Harrison et al. Contemporary Clinical Trials
- Chymase as a Possible Therapeutic Target for Amelioration of Non-Alcoholic Steatohepatitis
- (2020) Shinji Takai et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Pathophysiology of Type 2 Diabetes Mellitus
- (2020) Unai Galicia-Garcia et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Discovery of PF-06835919: A Potent Inhibitor of Ketohexokinase (KHK) for the Treatment of Metabolic Disorders Driven by the Overconsumption of Fructose
- (2020) Kentaro Futatsugi et al. JOURNAL OF MEDICINAL CHEMISTRY
- FGF19 and FGF21: In NASH we trust
- (2020) Saswata Talukdar et al. Molecular Metabolism
- Chronic Inflammation in Non-Alcoholic Steatohepatitis: Molecular Mechanisms and Therapeutic Strategies
- (2020) Carmelo Luci et al. Frontiers in Endocrinology
- Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH
- (2020) Rohit Loomba et al. HEPATOLOGY
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis
- (2020) Philip N. Newsome et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Role of Innate Immune Cells in Nonalcoholic Steatohepatitis
- (2019) Jingjing Cai et al. HEPATOLOGY
- Homeostasis of Glucose and Lipid in Non-Alcoholic Fatty Liver Disease
- (2019) Hsu-Wen Chao et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Effects of vitamin D supplementation on liver fibrogenic factors in non-alcoholic fatty liver patients with steatohepatitis: study protocol for a randomized clinical trial
- (2019) Soraiya Ebrahimpour-Koujan et al. Trials
- A Structured Literature Review of the Epidemiology and Disease Burden of Non-Alcoholic Steatohepatitis (NASH)
- (2019) Manca Povsic et al. ADVANCES IN THERAPY
- Unexpected Rapid Increase in the Burden of Nonalcoholic Fatty Liver Disease in China From 2008 to 2018: A Systematic Review and Meta‐Analysis
- (2019) Feng Zhou et al. HEPATOLOGY
- Role of Vitamin E for Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes: A Randomized Controlled Trial
- (2019) Fernando Bril et al. DIABETES CARE
- GS-0976 (Firsocostat): an investigational liver-directed acetyl-CoA carboxylase (ACC) inhibitor for the treatment of non-alcoholic steatohepatitis (NASH)
- (2019) Naim Alkhouri et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development
- (2019) Juliette Mouries et al. JOURNAL OF HEPATOLOGY
- CONTROL: A randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients
- (2019) Paul J. Pockros et al. LIVER INTERNATIONAL
- Vitamin E is an effective treatment for nonalcoholic steatohepatitis in HIV mono-infected patients
- (2019) Giada Sebastiani et al. AIDS
- Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study
- (2019) Stephen A. Harrison et al. JOURNAL OF HEPATOLOGY
- Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
- (2019) Stephen A Harrison et al. LANCET
- Targeting diacylglycerol acyltransferase 2 for the treatment of nonalcoholic steatohepatitis
- (2019) Neeta B. Amin et al. Science Translational Medicine
- Polyphenol Effects on Cholesterol Metabolism via Bile Acid Biosynthesis, CYP7A1: A Review
- (2019) Karen F. Chambers et al. Nutrients
- Diversification of host bile acids by members of the gut microbiota
- (2019) Jenessa A. Winston et al. Gut Microbes
- Cenicriviroc for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis: AURORA Phase 3 study design
- (2019) Quentin M. Anstee et al. Contemporary Clinical Trials
- Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension
- (2019) Guadalupe Garcia-Tsao et al. JOURNAL OF HEPATOLOGY
- A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis
- (2019) Stephen A. Harrison et al. JOURNAL OF HEPATOLOGY
- Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
- (2019) Zobair M Younossi et al. LANCET
- Anti-NASH Drug Development Hitches a Lift on PPAR Agonism
- (2019) Joost Boeckmans et al. Cells
- Histological improvement of non-alcoholic steatohepatitis with a prebiotic: a pilot clinical trial
- (2018) Marc R. Bomhof et al. EUROPEAN JOURNAL OF NUTRITION
- Simtuzumab Is Ineffective for Patients with Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis
- (2018) Stephen A. Harrison et al. GASTROENTEROLOGY
- Non-alcoholic steatohepatitis pathogenesis: sublethal hepatocyte injury as a driver of liver inflammation
- (2018) Samar H Ibrahim et al. GUT
- A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis
- (2018) Scott L. Friedman et al. HEPATOLOGY
- Nonalcoholic fatty liver disease incidence and impact on metabolic burden and death: A 20 year-community study
- (2018) Alina M. Allen et al. HEPATOLOGY
- Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers
- (2018) Eduardo Vilar-Gomez et al. JOURNAL OF HEPATOLOGY
- Determinants of fibrosis progression and regression in NASH
- (2018) Detlef Schuppan et al. JOURNAL OF HEPATOLOGY
- Monoacylglycerol Acyltransferase 2 (MGAT2) Inhibitors for the Treatment of Metabolic Diseases and Nonalcoholic Steatohepatitis (NASH)
- (2018) Pratik Devasthale et al. JOURNAL OF MEDICINAL CHEMISTRY
- NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
- (2018) Stephen A Harrison et al. LANCET
- Triggering and resolution of inflammation in NASH
- (2018) Susanne Schuster et al. Nature Reviews Gastroenterology & Hepatology
- Role of gut microbiota and oxidative stress in the progression of non-alcoholic fatty liver disease to hepatocarcinoma: Current and innovative therapeutic approaches
- (2018) Antonella Borrelli et al. Redox Biology
- Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial
- (2018) Patrick M O'Neil et al. LANCET
- Utility and variability of three non-invasive liver fibrosis imaging modalities to evaluate efficacy of GR-MD-02 in subjects with NASH and bridging fibrosis during a phase-2 randomized clinical trial
- (2018) Stephen A. Harrison et al. PLoS One
- Nutraceutical Approach to Non-Alcoholic Fatty Liver Disease (NAFLD): The Available Clinical Evidence
- (2018) Arrigo Cicero et al. Nutrients
- Ileal Bile Acid Transporter Inhibition for the Treatment of Chronic Constipation, Cholestatic Pruritus, and NASH
- (2018) Samer Al-Dury et al. Frontiers in Pharmacology
- Molecular pathways of nonalcoholic fatty liver disease development and progression
- (2018) Fernando Bessone et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Targeting Metabolism, Insulin Resistance, and Diabetes to Treat Nonalcoholic Steatohepatitis
- (2018) Brian N. Finck DIABETES
- The role of the microbiome in NAFLD and NASH
- (2018) Aleksandra A Kolodziejczyk et al. EMBO Molecular Medicine
- Non-alcoholic fatty liver disease – A global public health perspective
- (2018) Zobair M. Younossi JOURNAL OF HEPATOLOGY
- Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial
- (2018) Arun Sanyal et al. LANCET
- Absorption, Distribution, Metabolism, and Excretion of [14C]-Volixibat in Healthy Men: Phase 1 Open-Label Study
- (2017) Nicholas Siebers et al. EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS
- Selective targeting of lysyl oxidase-like 2 (LOXL2) suppresses hepatic fibrosis progression and accelerates its reversal
- (2017) Naoki Ikenaga et al. GUT
- The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial
- (2017) Rohit Loomba et al. HEPATOLOGY
- The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
- (2017) Naga Chalasani et al. HEPATOLOGY
- Current and future pharmacological therapies for NAFLD/NASH
- (2017) Yoshio Sumida et al. JOURNAL OF GASTROENTEROLOGY
- The role of bile acids in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
- (2017) Monica D. Chow et al. MOLECULAR ASPECTS OF MEDICINE
- A randomised controlled trial of losartan as an anti-fibrotic agent in non-alcoholic steatohepatitis
- (2017) Stuart McPherson et al. PLoS One
- Insights into Stearoyl-CoA Desaturase-1 Regulation of Systemic Metabolism
- (2017) Ahmed M. ALJohani et al. TRENDS IN ENDOCRINOLOGY AND METABOLISM
- Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus
- (2016) Kenneth Cusi et al. ANNALS OF INTERNAL MEDICINE
- Pharmacokinetics, Safety, and CCR2/CCR5 Antagonist Activity of Cenicriviroc in Participants With Mild or Moderate Hepatic Impairment
- (2016) E Lefebvre et al. CTS-Clinical and Translational Science
- Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives
- (2016) Juan P. Arab et al. HEPATOLOGY
- Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes
- (2016) Zobair M. Younossi et al. HEPATOLOGY
- Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis
- (2016) Matthew J. Armstrong et al. JOURNAL OF HEPATOLOGY
- The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)
- (2016) Elena Buzzetti et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- The role of immune cells in metabolism-related liver inflammation and development of non-alcoholic steatohepatitis (NASH)
- (2016) Marina Nati et al. REVIEWS IN ENDOCRINE & METABOLIC DISORDERS
- The Role of Cholesterol in the Pathogenesis of NASH
- (2016) George N. Ioannou TRENDS IN ENDOCRINOLOGY AND METABOLISM
- Effects of Moderate and Vigorous Exercise on Nonalcoholic Fatty Liver Disease
- (2016) Hui-Jie Zhang et al. JAMA Internal Medicine
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomized, placebo-controlled phase 2 study
- (2016) Jaimini Cegla ANNALS OF CLINICAL BIOCHEMISTRY
- Molecular Pathways: Fatty Acid Synthase
- (2015) S. F. Jones et al. CLINICAL CANCER RESEARCH
- The regulation of function, growth and survival of GLP-1-producing L-cells
- (2015) R. E. Kuhre et al. CLINICAL SCIENCE
- High-dose vitamin D supplementation and liver histology in NASH: Table 1
- (2015) Matthew T Kitson et al. GUT
- Vascular adhesion protein 1 in nonalcoholic steatohepatitis: A novel biomarker?
- (2015) Natalie J. Torok HEPATOLOGY
- Nonalcoholic Fatty Liver Disease
- (2015) Mary E. Rinella JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Current efforts and trends in the treatment of NASH
- (2015) Vlad Ratziu et al. JOURNAL OF HEPATOLOGY
- Effects of n-3 fish oil on metabolic and histological parameters in NASH: A double-blind, randomized, placebo-controlled trial
- (2015) Curtis K. Argo et al. JOURNAL OF HEPATOLOGY
- Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease
- (2015) Michal Pawlak et al. JOURNAL OF HEPATOLOGY
- Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
- (2015) Brent A Neuschwander-Tetri et al. LANCET
- Beneficial effects of mineralocorticoid receptor blockade in experimental non-alcoholic steatohepatitis
- (2015) Margarita Pizarro et al. LIVER INTERNATIONAL
- Bile Acid-Activated Receptors, Intestinal Microbiota, and the Treatment of Metabolic Disorders
- (2015) Stefano Fiorucci et al. TRENDS IN MOLECULAR MEDICINE
- Cardiovascular risk assessment in the treatment of nonalcoholic steatohepatitis: a secondary analysis of the MOZART trial
- (2015) Steven C. Lin et al. Therapeutic Advances in Gastroenterology
- The Emerging Landscape of RORγt Biology
- (2014) Jacob S. Lee et al. IMMUNITY
- Characteristics of hepatic fatty acid compositions in patients with nonalcoholic steatohepatitis
- (2014) Kazutoshi Yamada et al. LIVER INTERNATIONAL
- Thyroid Hormone Regulation of Metabolism
- (2014) Rashmi Mullur et al. PHYSIOLOGICAL REVIEWS
- Decoding cell death signals in liver inflammation
- (2013) Catherine Brenner et al. JOURNAL OF HEPATOLOGY
- Eltrombopag before Procedures in Patients with Cirrhosis and Thrombocytopenia
- (2012) Nezam H. Afdhal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Opposing effects of fructokinase C and A isoforms on fructose-induced metabolic syndrome in mice
- (2012) T. Ishimoto et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Pentoxifylline improves nonalcoholic steatohepatitis: A randomized placebo-controlled trial
- (2011) Claudia O. Zein et al. HEPATOLOGY
- An apoptosis panel for nonalcoholic steatohepatitis diagnosis
- (2010) Tarek I. Abu-Rajab Tamimi et al. JOURNAL OF HEPATOLOGY
- Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
- (2010) NEW ENGLAND JOURNAL OF MEDICINE
- Molecular mechanism for the regulation of human ACC2 through phosphorylation by AMPK
- (2009) Yong Soon Cho et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: Results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial
- (2009) Vlad Ratziu et al. HEPATOLOGY
- Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis
- (2008) R. LOOMBA et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search